Moreau, P., Stewart, K. A., Dimopoulos, M., Siegel, D., Facon, T., Berenson, J., . . . Mateos, M. (2020). Once‐weekly (70 mg/m(2)) vs twice‐weekly (56 mg/m(2)) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials. Cancer Med.
Chicago Style CitationMoreau, Philippe, et al. "Once‐weekly (70 Mg/m(2)) Vs Twice‐weekly (56 Mg/m(2)) Dosing of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma: A Post Hoc Analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 Trials." Cancer Med 2020.
MLA CitationMoreau, Philippe, et al. "Once‐weekly (70 Mg/m(2)) Vs Twice‐weekly (56 Mg/m(2)) Dosing of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma: A Post Hoc Analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 Trials." Cancer Med 2020.